Study: Vitamin D deficiency possible predictor of aggressive prostate cancer
NEW YORK — Vitamin D deficiency could be a predictor for aggressive prostate cancer, according to a study funded by the National Institutes of Health and the U.S. Department of Defense. In examining the prostate biopsy results of men with abnormal prostate-specific antigen levels and/or digital rectal exams, researchers discovered that men with low vitamin D levels were more likely to develop aggressive prostate cancer and to be diagnosed with advanced-stage tumors.
"The good news is that vitamin D deficiency is very easy to address," said David Samadi, chairman of urology and chief of robotic surgery at Lenox Hill Hospital. "If we look at low vitamin D as a potential biomarker for prostate cancer and add it to annual blood panels, we can identify men who need to boost their levels. Increasing vitamin D levels is easily accomplished through supplements and even good old fashioned sun exposure."
Among the 600 Chicago-area study participants, African-American men with low vitamin D levels were almost five times more likely to have aggressive prostate cancer; European-American men with low levels were more than three times as likely. Both groups also showed increased odds of more advanced tumor staging at diagnosis; more than four times and nearly three times more likely for African-American and European-American men, respectively.
The vitamin D prostate cancer study was led by Northwestern Medicine and the University of Illinois at Chicago. Results were published in the May 1 Clinical Cancer Research journal by the American Association for Cancer Research.
Colgate Total, chef Lorena Garcia team up to engage foodies
NEW YORK — Colgate Total has teamed up with celebrity chef Lorena Garcia to engage foodies across the country and guide them on the path to a healthy mouth and palate.
Colgate added Colgate Total Mouthwash to its portfolio of oral care products last year and this new partnership will kick off at the annual BlogHer Food Conference in Miami on Friday, May 16.
At the conference, Lorena will be dishing up recipes at the Colgate Total booth, conducting blind taste tests and sharing the benefits of Colgate Total Mouthwash. Lorena will also appear at another major food festival later this summer, the Big Apple Barbecue Block Party in New York City.
Lundbeck set to acquire Chelsea Therapeutics
VALBY, Denmark and CHARLOTTE, N.C. — Lundbeck and Chelsea Therapeutics International last week announced an agreement under which Lundbeck will acquire Chelsea.
The transaction will allow Lundbeck to leverage its experience in rare neurologic disorders in the United States through the upcoming launch of Northera, which received approval from the Food and Drug Administration on Feb. 18. The drug is used for the treatment of symptomatic neurogenic orthostatic hypotension and is expected to launch in the second half of 2014. Northera will join Lundbeck’s existing line of neurology medications, which includes Onfi, Sabril and Xenazine.
"I believe this offer represents an attractive offer to the stockholders of Chelsea and is consistent with Lundbeck’s strategic and disciplined approach to acquisitions," said Ulf Wiinberg, president and CEO Lundbeck. "The proposed strategic acquisition of Chelsea — and the launch of its lead therapy, Northera — aligns with Lundbeck’s core strengths in addressing rare and challenging neurological disorders. As a company committed to people living with brain disorders, we are uniquely positioned to make Northera available to those who need it most."
Chelsea stockholders are entitled to $6.44 per share in cash and CVRs that may pay up to $1.50, for a total potential consideration of up to $ 7.94 per share, or $658 million on a fully diluted basis, the companies stated. The offer also provides Chelsea stockholders to participate in the potential commercial success of Northera.
Chelsea’s board of directors unanimously approved the transaction, which is expected to close in the third quarter of 2014.